A new review in Genes & Diseases examines how scientists are turning a deeper understanding of X chromosome inactivation into potential treatments for X-linked genetic disorders. The process, which normally prevents females from producing twice as many X chromosome-linked proteins as males, may also conceal healthy copies of genes that could compensate for disease-causing mutations. Researchers are now exploring whether manipulating this natural silencing system could restore gene activity in conditions including Rett syndrome, Fabry disease, hemophilia, muscular dystrophy and X-linked immune disorders.
X chromosome inactivation begins early in embryonic development in female mammals, when each cell generally shuts down one of its two X chromosomes. The choice is usually random, producing a mosaic of cells in which either the maternal or paternal X chromosome remains active. Once established, the inactive chromosome is maintained through cell division by a combination of DNA methylation, histone modifications and changes in three-dimensional chromatin organization. This creates a stable but highly regulated state in which most genes on the inactive chromosome are inaccessible to the cell’s transcriptional machinery.
A central coordinator of this process is XIST, a long non-coding RNA produced from the X chromosome destined for inactivation. Rather than encoding a protein, XIST spreads across the chromosome from which it is transcribed and recruits molecular complexes that remodel chromatin. These complexes include proteins involved in histone deacetylation, Polycomb-mediated repression and DNA methylation. Together, they convert the chromosome into a compact structure known as heterochromatin. Although XIST is essential for silencing most X-linked genes, some genes escape inactivation, an important feature that contributes to biological differences between individuals.
The consequences of X chromosome inactivation become particularly visible when a woman carries a mutation in an X-linked gene. If the chromosome carrying the mutation is preferentially silenced, cells may continue to use the healthy copy, limiting disease manifestations. If the normal chromosome is silenced instead, a larger proportion of cells may express the mutant allele. This uneven pattern, known as skewed X chromosome inactivation, can arise through chance during development or through selective survival of cells carrying one active chromosome. It helps explain why people with the same genetic mutation can experience substantially different symptoms.
Rett syndrome provides one of the clearest examples. The disorder is usually caused by mutations in MECP2, a gene that encodes a protein involved in interpreting DNA methylation and regulating neuronal gene expression. In female carriers, the proportion of neurons expressing mutant or healthy MECP2 can strongly influence neurological function. Preferential inactivation of the chromosome with the faulty MECP2 gene may reduce symptoms, while inactivation of the chromosome carrying the normal gene can intensify them. Experimental studies in animal models have further suggested that restoring healthy MECP2 activity after disease features have appeared may reverse some neurological and behavioral abnormalities.
The review also describes evidence connecting X chromosome inactivation with disease severity in Fabry disease, Becker muscular dystrophy, hemophilia, X-linked Alport syndrome and chronic granulomatous disease. However, the relationship is not always straightforward. X chromosome patterns can differ between tissues, and a blood sample may not accurately represent what occurs in the brain, heart, kidneys or skeletal muscle. Age, tissue-specific selection and the expansion of particular cell populations can also alter the balance over time. These complications make it difficult to use a single X chromosome inactivation measurement as a universal predictor of clinical outcome.
Improved measurement technologies are therefore becoming essential. The HUMARA assay, which analyzes methylation near a polymorphic region of the androgen receptor gene, has long been used as a convenient indirect estimate of X chromosome activity. Bisulfite sequencing can provide more detailed information about methylated DNA, while RNA-based methods can reveal which alleles are actively transcribed. More recently, long-read nanopore sequencing combined with CRISPR-Cas9 enrichment has offered a way to examine selected genomic regions while simultaneously assessing DNA methylation. Such methods could eventually help clinicians identify patients whose healthy alleles remain available for therapeutic reactivation.
The most ambitious strategy is to awaken selected genes on the inactive X chromosome without globally disrupting the chromosome’s silencing system. This distinction is critical because broad X chromosome reactivation could produce excessive gene expression and potentially harmful cellular effects. Researchers are investigating targeted approaches involving antisense molecules, genome-editing systems, epigenetic drugs and manipulation of XIST-associated pathways. In cellular and animal models of Rett syndrome, reactivation of the silent healthy MECP2 allele has demonstrated the principle that an inactive gene may remain therapeutically recoverable long after embryonic development.
The review highlights ACVR1 and PDPK1 among the signaling and regulatory factors being studied as possible intervention points. In experimental systems, inhibiting these pathways has influenced XIST expression, chromatin structure and the accessibility of genes on the inactive chromosome. Some studies have reported partial restoration of gene activity and improvements in disease-related cellular abnormalities. Translating these findings into human therapies will require precise delivery, tissue-specific control and careful monitoring of unintended gene activation. Even so, X chromosome biology is moving from a fundamental topic in developmental genetics toward a possible platform for personalized treatment, in which a patient’s inactivation pattern could determine whether a silenced healthy gene can be safely brought back online.
Subject of Research: X chromosome inactivation, skewed X chromosome inactivation and therapeutic reactivation of genes on the inactive X chromosome in X-linked genetic disorders.
Article Title: From inactivation to intervention: X chromosome silencing in disease pathogenesis and emerging therapeutic strategies
Web References: https://doi.org/10.1016/j.gendis.2025.101964; https://www.sciencedirect.com/journal/genes-and-diseases
References: Yuan Fu, Xuling Tan, Lixia Qin, Chunyu Wang, “From inactivation to intervention: X chromosome silencing in disease pathogenesis and emerging therapeutic strategies,” Genes & Diseases, Volume 13, Issue 5, 2026, Article 101964.
Image Credits: Genes & Diseases
Keywords: X chromosome inactivation, XCI, skewed XCI, XIST, Rett syndrome, MECP2, Fabry disease, hemophilia, muscular dystrophy, gene reactivation, epigenetics, CRISPR-Cas9, nanopore sequencing, X-linked disorders
Tags: chromatin modificationsepigenetic regulationFabry disease potentialgene silencinggene therapy for X-linked diseaseshemophilia gene reactivationmuscular dystrophy researchRett syndrome treatmenttargeted epigenetic therapiesX chromosome inactivationX-linked genetic disordersXIST long non-coding RNA
